Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo (NYSE: PRGO) is scheduled to participate in investor meetings at the Jefferies Miami Consumer Conference on November 18, 2026. Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to represent the company.
Perrigo (NYSE: PRGO) reported third-quarter net sales of $989 million, with lower sales and margins accompanying a diluted loss. Sales fell 5.2% year over year in the quarter ended September 26, 2026. Reported diluted EPS was $(0.10), versus $0.09; adjusted EPS fell 25.0% to $0.60. Core sales, excluding Infant Formula and previously announced divestitures, declined 1.7% to $908 million.
Perrigo agreed to sell Infant Formula for up to $175 million: $40 million at closing and up to $135 million tied to sales milestones through 2030. It expects a fourth-quarter impairment loss of $275 million–$375 million. Core 2026 adjusted EPS guidance fell to $2.15–$2.35 from $2.25–$2.55, reflecting retailer inventory caution and European consumer softness. Quarterly operating cash flow was $96 million; cash was $437 million against $3.3 billion of debt. The Oral Care strategic review remains ongoing.
Perrigo (NYSE: PRGO) announced that its Board of Directors approved a quarterly cash dividend of $0.29 per share. The dividend is payable on December 15, 2026, to shareholders of record on November 27, 2026. The quarterly amount represents $1.16 per share on an annualized basis.
Perrigo (NYSE: PRGO) agreed to sell its Infant Formula business to MeridianMade for total consideration of up to $175 million. The definitive agreement provides $40 million in cash at closing and up to $135 million contingent on future performance milestones through 2030. Closing is expected in the first half of 2027, subject to regulatory approvals and customary closing conditions.
Perrigo expects the divestiture to enhance its margin profile and bring future reported results closer to Core Perrigo, which excludes Infant Formula and certain previously announced divestitures and exited products. The company expects a $275 million to $375 million non-cash impairment charge in the fourth quarter of 2026. Infant Formula generated $380 million in net sales and $8 million in segment adjusted operating income in the trailing four quarters ended June 27, 2026.
Perrigo (NYSE: PRGO) plans to release its third quarter 2026 financial results on Wednesday, November 4, 2026. A conference call will begin at 8:30 a.m. ET, hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra, with a live webcast available through the company’s investor relations website.
Perrigo (NYSE: PRGO) announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10, 2026. The company describes itself as a leading pure-play self-care business focused on over-the-counter health and wellness products for consumers in North America and Europe.
Perrigo (NYSE: PRGO) reported second quarter 2026 results from continuing operations, highlighting ongoing execution of its Three-S plan, portfolio simplification and debt reduction. All In reported net sales were $1.02 billion, down 3.2% year-over-year, while Core net sales declined 3.1% to $907 million. Organic All In net sales fell 1.3% and Core organic net sales declined 3.5%. Reported gross margin decreased to 30.7% and reported operating margin to 2.3%, mainly due to lower volumes, planned under absorption and unfavorable mix. Reported diluted EPS rose to $0.63, helped by the gain on the Dermacosmetics divestiture, while All In adjusted EPS declined to $0.50 and Core adjusted EPS to $0.46. Infant Formula net sales grew 23.1% with operating income improving, and the company applied most of the approximately $359 million Dermacosmetics proceeds to reduce debt, ending the quarter with $400 million in cash and $3.3 billion in total debt. Perrigo reaffirmed its full-year 2026 outlook, including All In adjusted EPS guidance of $2.00–$2.30 and Core adjusted EPS of $2.25–$2.55, and expects a sequentially stronger second half.
Perrigo (NYSE: PRGO) announced that its Board of Directors approved a quarterly cash dividend of $0.29 per share, equivalent to $1.16 per share on an annualized basis. The dividend is payable on September 15, 2026 to shareholders of record as of August 28, 2026.
Perrigo (NYSE: PRGO) announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will present at the Canaccord 46th Annual Growth Conference on Wednesday, August 12 at 10:30 AM EDT. The presentation will be webcast via the Perrigo investor relations website.
Perrigo describes itself as a leading pure-play self-care company focused on over-the-counter health and wellness products in North America and Europe, leveraging cash-generative store-brand private label offerings to invest in branded products such as Opill, Mederma, Compeed, EllaOne, and Jungle Formula.
Perrigo (NYSE: PRGO) plans to release its second quarter 2026 financial results on Wednesday, August 5, 2026, followed by a conference call at 8:30 a.m. EST hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra. The live earnings call will be accessible via webcast in Perrigo’s investor relations section and by telephone, with replay available from approximately 12:00 p.m. EST on August 5 through August 12, 2026.